NCT02140437撤回2 期
An Open-label, Multi-center, Randomized Phase II Study of Fulvestrant Anastrozole Combination Versus Anastrozole Alone in Patients With Luminal A-like Postmenopausal Advanced Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- PFS(Progression free survival)
研究概览
简要总结
This research is designed to investigate whether the addition of fulvestrant 500mg to anastrozole is better than anastrozole alone as first-line endocrine therapy for advanced breast cancer.
详细描述
Anastrozole is the standard first-line endocrine treatment for patients with hormonal receptor positive advanced breast cancer. It has been proven that the addition of fulvestrant 250mg can enhance PFS of anastrozole monotherapy according to SWOG0226 study. However, the optimal recommended dose of fulvestrant for patients with advanced breast cancer is 500mg worldwide according to CONFIRM study. The investigator designed this research to investigate whether high dose fulvestrant can further improve efficacy of anastrozole monotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Histologically confirmed breast cancer
- •Luminal A-like breast cancer (primary or metastatic tumor), defined as: ER-positive, PR-positive (> 20%), Her-2 negative and Ki67 <14%.
- •Advanced breast cancer is eligible:
- •Endocrine therapy-naive patients with locally advanced disease, who are not suitable for radical surgery or radiotherapy (the decision made by the multidisciplinary breast cancer team). Prior first-line cytotoxic chemotherapy is acceptable. or
- •Patients with recurrent or metastatic disease, who have not received adjuvant endocrine therapy or who have been 2 years or longer after stop of adjuvant endocrine therapy. Patients who had disease progression from first-line cytotoxic chemotherapy are allowed.
- •At least one lesion (measurable and / or non-measurable) can be assessed at baseline, and is suitable for repeated assessments with CT and/or MRI.
- •Postmenopausal women, defined as any one of the following criteria (as defined in the NCCN's menopause definition):
- •previous bilateral oophorectomy
- •60 years old or older
- •less than 60 years old, amenorrheic for 12 months or longer in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression and follicle-stimulating hormone and estradiol in the postmenopausal range.
- •If taking tamoxifen, or toremifene and age < 60, then FSH and E in the postmenopausal range
- •ECOG 0, 1 or
- •Patients with good compliance.
- •Must be able to swallow tablets.
- •Without any significant gastrointestinal obstruction or dysfunction of absorption for oral drug.
排除标准
- •Life-threatening metastatic visceral disease, defined as extensive liver involvement or any degree of brain or leptomeningeal involvement (past or present) or symptomatic pulmonary lymphatic metastasis. If the investigator believe that their respiratory function is not significantly impaired due to illness, patients with scattered parenchymal metastases are qualified.
- •Have received any systemic treatment other than first-line cytotoxic chemotherapy.
- •Radiation therapy within 28 days prior to randomization (exception: radiotherapy to control bone pain, but should be completed before the randomization).
- •Use any other anti-cancer therapy at the same time (except bisphosphonate).
- •Previous endocrine treatment for advanced breast cancer.
- •Current or previous malignancy ( except for breast cancer, basal cell or squamous cell carcinoma of the skin with adequate treatment, cervical carcinoma in situ).
- •Inadequate blood or liver or renal function within one week prior to randomization: Platelets < 80 × 10^9/L; Total bilirubin > 1.5 × (ULRR) (patients with Gilbert's syndrome is eligible); or ALT or AST > 2.5 × ULRR (without liver metastases) or > 5 × ULRR (with liver metastases).
- •History with hemorrhagic constitution (e.g. disseminated intravascular coagulation, clotting factor deficiency) or long-term anticoagulant therapy.
- •Hypersensitivity history to excipients or castor oil of fulvestrant or anastrozole.
- •Any other severe co-existing medical disorders, ie uncontrolled heart disease.
- •Participation in any clinical trial and / or exposure to any investigational medication within 28 days before randomization.
研究组 & 干预措施
Fulvestrant and anastrozole
Experimental
Anastrozole 1 mg PO QD Fulvestrant 500mg IM d1,15, 29 and 4 weeks after
干预措施: Fulvestrant (Drug)
Fulvestrant and anastrozole
Experimental
Anastrozole 1 mg PO QD Fulvestrant 500mg IM d1,15, 29 and 4 weeks after
干预措施: Anastrozole (Drug)
Anastrozole
Active Comparator
Anastrozole 1 mg PO QD
干预措施: Anastrozole (Drug)
结局指标
主要结局
PFS(Progression free survival)
时间窗: 8 weeks
次要结局
- OS(overall survival )(8 weeks)
研究者
相似试验
已完成
2 期
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.Invasive Breast CancerNCT00921115University of Kansas Medical Center42
进行中（未招募）
3 期
A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.Hormone Receptor Positive Breast CancerNCT01602380AstraZeneca462
终止
2 期
Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung CancerPostmenopausal WomenNon-small Cell Lung CancerNCT00932152University of Pittsburgh3
进行中（未招募）
3 期
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.Breast CancerNCT00099437AstraZeneca736
已完成
3 期
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer WomenBreast CancerNCT01300351AstraZeneca249